

Caplin Point Laboratories Limited CORPORATE OFFICE : Ashvich Tower, 3rd Floor, No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096. Phone : +91 44 24968000 / +91 80127 72888 E-mail : info@caplinpoint.net / Website : www.caplinpoint.net CIN : L24231TN1990PLC019053

18.07.2019

BSE Limited Department of Corporate Relationship 1st Floor, New Trade Ring, Rotunda Building Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code : 524742

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051 *Scrip Code : CAPLIPOINT*.

By NEAPS

By BSE Listing

Dear Sirs,

SUB: PRESS RELEASE- DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Please find the enclosed copy of Press Release being published today.

Kindly take the same on your records.

Thanking You,

Yours Faithfully, For Caplin Point Laboratories Limited

Company Secretary

Enclosure: As above

Regd. Off.: "NARBAVI", No. 3, Lakshmanan Street, T.Nagar, Chennai - 600 017. Tamil Nadu, India. Ph.: +91 44 28156653.Unit I: No. 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: 95242 32888 / 95242 32006.Unit II: No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9445391317.Unit III: Plot No. 44, 8th Avenue, Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Kanchipuram District-603 004.Unit IV: Survey No. 895 & 897, Guruvarajakandigai, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9788459333 / 69333.Unit V: Ashvich Tower, 2nd Floor, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096. Ph.: +91 44 24968000.



PRESS RELEASE

CAPLIN STERILES GETS USFDA APPROVAL FOR TRANEXAMIC ACID INJECTION

Chennai, Jul 18, 2019: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tranexamic Acid Injection USP, 1000mg/10mL (100mg/mL) vial, a generic therapeutic equivalent version of Cyklokapron Injection, 100 mg/mL, of Pharmacia & Upjohn Company.

Tranexamic Acid Injection is administered in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

According to IQVIA (IMS Health), Tranexamic Acid had US sales data of approximately \$30 million for the 12 month period ending March 2019. Caplin Steriles, has developed and filed 11 ANDAs on its own and with partners, with 5 approvals so far. The company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, to be filed over the next 4 years.

ABOUT CAPLIN POINT LABORATORIES LIMITED:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The company has over 2800 product approvals across the globe with another 250+ in the pipeline. The company's subsidiary Caplin Steriles Ltd caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point Laboratories Limited has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forwardlooking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

